SAR Stock Overview
A clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sareum Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.28 |
| 52 Week High | UK£0.84 |
| 52 Week Low | UK£0.10 |
| Beta | -1.08 |
| 11 Month Change | -5.08% |
| 3 Month Change | -15.79% |
| 1 Year Change | -65.00% |
| 33 Year Change | -91.58% |
| 5 Year Change | 75.00% |
| Change since IPO | -81.33% |
Recent News & Updates
Recent updates
Here's Why We're Not Too Worried About Sareum Holdings' (LON:SAR) Cash Burn Situation
Aug 24
We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate
Apr 27Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans
Aug 06We Think Sareum Holdings (LON:SAR) Can Afford To Drive Business Growth
Apr 22Sareum Holdings (LON:SAR) Is In A Good Position To Deliver On Growth Plans
Jan 06We're Not Very Worried About Sareum Holdings' (LON:SAR) Cash Burn Rate
Aug 31We're Hopeful That Sareum Holdings (LON:SAR) Will Use Its Cash Wisely
May 07What Type Of Shareholders Own The Most Number of Sareum Holdings plc (LON:SAR) Shares?
Dec 23
Shareholder Returns
| SAR | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | 3.7% | -1.8% | -1.3% |
| 1Y | -65.0% | 3.4% | 6.1% |
Return vs Industry: SAR underperformed the UK Pharmaceuticals industry which returned 5.8% over the past year.
Return vs Market: SAR underperformed the UK Market which returned 9.5% over the past year.
Price Volatility
| SAR volatility | |
|---|---|
| SAR Average Weekly Movement | 5.7% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 9.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SAR has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: SAR's weekly volatility has decreased from 17% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 5 | n/a | www.sareum.com |
Sareum Holdings plc, a clinical stage small molecule drug development company, engages in the discovery and development of therapeutic drugs for cancer and autoimmune diseases. It develops small molecule therapeutic drugs based on its Sareum Kinase Inhibitor Library drug discovery platform. The company’s lead product is SDC-1801, a TYK2/JAK1 inhibitor that is in a Phase 1a clinical trials for the treatment of autoimmune diseases.
Sareum Holdings plc Fundamentals Summary
| SAR fundamental statistics | |
|---|---|
| Market cap | UK£30.22m |
| Earnings (TTM) | -UK£4.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.1x
P/E RatioIs SAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SAR income statement (TTM) | |
|---|---|
| Revenue | UK£0 |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£0 |
| Other Expenses | UK£4.26m |
| Earnings | -UK£4.25m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SAR perform over the long term?
See historical performance and comparison